Valproic acid does not affect markers of human immunodeficiency virus disease progression
- Cite this article as:
- Ances, B.M., Letendre, S., Buzzell, M. et al. Journal of NeuroVirology (2006) 12: 403. doi:10.1080/13550280600981695
- 43 Downloads
Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.